Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1786066 | 0.91 | BTK (0.44) | BTKKMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL1783861 | 0.90 | BTK (0.45) | BTKKMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL1786038 | 0.88 | BTK (0.56) | BTKALDH1A1MAPTHPGDHTT | |
| SCHEMBL1782535 | 0.86 | BTK (0.48) | BTKKMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL1782589 | 0.85 | BTK (0.43) | BTKKMT2AL3MBTL1ALDH1A1MAPT | |
| SCHEMBL1784111 | 0.82 | BTK (0.68) | BTK | |
| SCHEMBL1783650 | 0.79 | BTK (0.52) | BTKALDH1A1MAPTHPGDHTT | |
| SCHEMBL3316080 | 0.78 | CCNA2 (0.45) | BTKALDH1A1MAPTHPGDHTT | |
| SCHEMBL1786244 | 0.75 | BTK (0.64) | BTK | |
| SCHEMBL1785917 | 0.75 | BTK (0.55) | BTKKMT2AL3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476430-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2323665-B1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20110124640-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | disclosed |
| EP-2323665-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | Bristol-Myers Squibb Company (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010011837-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124640-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BTK, LYN, ABL1 | BTK 1/4885KMT2A 715/4885L3MBTL1 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.